189 related articles for article (PubMed ID: 8371139)
1. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
2. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the beta-adrenoceptor system and reactive oxygen species.
de Jong J; Schoofs PR; Onderwater RC; van der Vijgh WJ; Pinedo HM; Bast A
Res Commun Chem Pathol Pharmacol; 1990 Jun; 68(3):275-89. PubMed ID: 2166963
[TBL] [Abstract][Full Text] [Related]
3. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
4. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
5. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
6. The influence of doxorubicin and 4'-epi-doxorubicin on lipid peroxidation in mouse heart, lungs and liver. Part II.
Pierściński G; Drzewoski J; Nowak D
Pol J Pharmacol; 1994; 46(1-2):55-9. PubMed ID: 7981772
[TBL] [Abstract][Full Text] [Related]
7. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
9. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.
Zou Y; Priebe W; Stephens LC; Perez-Soler R
Clin Cancer Res; 1995 Nov; 1(11):1369-74. PubMed ID: 9815933
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
[TBL] [Abstract][Full Text] [Related]
12. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios.
Dorr RT; Bozak KA; Shipp NG; Hendrix M; Alberts DS; Ahmann F
Cancer Res; 1988 Sep; 48(18):5222-7. PubMed ID: 3409247
[TBL] [Abstract][Full Text] [Related]
13. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
14. Reduction of adriamycin cardiotoxicity by enoximone.
Bossa R; Bissoli M; Chiericozzi M; Cozzi R; Galatulas I; Salvatore G
Anticancer Res; 1996; 16(1):141-3. PubMed ID: 8615599
[TBL] [Abstract][Full Text] [Related]
15. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
17. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR
Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
19. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats.
Zordoky BN; Anwar-Mohamed A; Aboutabl ME; El-Kadi AO
Toxicol Appl Pharmacol; 2010 Jan; 242(1):38-46. PubMed ID: 19796650
[TBL] [Abstract][Full Text] [Related]
20. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
